Citation Impact
Citing Papers
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
2019 StandoutScienceNobel
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
2010 Standout
Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei
2004 Standout
Hypoxia-Inducible Carbonic Anhydrase IX and XII Promote Tumor Cell Growth by Counteracting Acidosis through the Regulation of the Intracellular pH
2008
Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
2015
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
2009
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
2015
Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion
2010 StandoutNobel
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
TOR Signaling in Growth and Metabolism
2006 Standout
Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies
2011
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors
2017
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
2013
The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks
2017 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
HER2Gene Amplification in Breast Cancer
2012
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
2012
Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity
2010
Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
2010
Cancer statistics, 2017
2017 Standout
Cancer statistics, 2018
2018 Standout
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
Myeloid Growth Factors
2011
Prevention of febrile neutropenia: use of prophylactic antibiotics
2009
Changing Concepts of Hormone Receptor–Positive Advanced Breast Cancer Therapy
2012
Targeting hypoxia in cancer therapy
2011 Standout
Estrogen receptors and human disease
2006 Standout
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Breast cancer
2016 Standout
Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics
2009
Marine-derived anticancer agents in clinical trials
2003
Breast-Conserving Surgery With or Without Radiotherapy in Older Breast Patients With Early Stage Breast Cancer: A Systematic Review and Meta-analysis
2013
Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer
2012 StandoutNobel
Hypoxia/reoxygenation: A dynamic regulator of lysyl oxidase‐facilitated breast cancer migration
2007
Review of survival analyses published in cancer journals
1995
Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA
2007
Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
2015
The rational design of potential chemotherapeutic agents: Synthesis of bryostatin analogues
1999
Antibiotic prophylaxis in neutropenic patients
2006
Second international consensus guidelines for breast cancer in young women (BCY2)
2016
The influence of natural products upon drug discovery (Antiquity to late 1999)
2000
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)
2017
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
2017
Hypoxia in cancer: significance and impact on clinical outcome
2007 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Carbonic anhydrases: novel therapeutic applications for inhibitors and activators
2008 Standout
Hindlimb Suspension and SPE-Like Radiation Impairs Clearance of Bacterial Infections
2014 StandoutNobel
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Hypoxia and cancer
2007
Oxygen, a source of life and stress
2007
Gastric cancer
2020 Standout
Microenvironmental regulation of metastasis
2008 Standout
The chemistry and biology of the bryostatin antitumour macrolides
2002
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER
2014
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
2017
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
2010
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
The PI3K Pathway in Human Disease
2017 Standout
Carbonic Anhydrase IX: Regulation and Role in Cancer
2013
Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution
2008
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence
2015
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial
2017
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Platelet–cancer interactions: mechanisms and pharmacology of tumour cell‐induced platelet aggregation
2004
‘Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases
2012
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
First international consensus guidelines for breast cancer in young women (BCY1)
2014
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
2007 Standout
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy
2009
A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis
2009
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
2015
Emerging targeted agents in metastatic breast cancer
2013
Fever of Unknown Origin in Febrile Leukopenia
2007
Progress in the Discovery of Biosynthetic Anticancer Drugs
1996
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study
2011
Targeting the mTOR Signaling Network for Cancer Therapy
2009
Prevention and Treatment of Cancer-Related Infections
2012
89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
2012
Selective Killing of Hypoxia-Inducible Factor-1–Active Cells Improves Survival in a Mouse Model of Invasive and Metastatic Pancreatic Cancer
2009 StandoutNobel
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
2010
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Total Synthesis of Bryostatin 2
1999
Breast Cancer Treatment
2019 Standout
Surgical treatment of primary breast cancer in the neoadjuvant setting
2014
Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers
2015
Combination therapy in combating cancer
2017 Standout
Cancer statistics, 2016
2016 Standout
Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline
2013
Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung Cancer
2006
Inhibitors of the mammalian target of rapamycin
2005
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression
2012 StandoutNobel
Aplidine: A Paradigm of how to Handle the Activity and Toxicity of a Novel Marine Anticancer Poison
2007
Estrogen Receptor Mutations in Human Disease
2004
Structure–Activity Relationships of C-17 Cyano-Substituted Estratrienes as Anticancer Agents
2008
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
2009
Synthesis and inhibition potency of novel ureido benzenesulfonamides incorporating GABA as tumor-associated carbonic anhydrase IX and XII inhibitors
2015
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Ureido-Substituted Benzenesulfonamides Potently Inhibit Carbonic Anhydrase IX and Show Antimetastatic Activity in a Model of Breast Cancer Metastasis
2011
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Synthesis and biological evaluation of bryostatin analogues: the role of the A-ring
2000
Discovery and Development of Antineoplastic Agents from Natural Sources
1989
Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
2012 Standout
Works of Daniel Rea being referenced
Time to stop operating on breast cancer patients with pathological complete response?
2013
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer
2007
Coagulopathic complications in breast cancer
2003
Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor Induction In Vivo
1993
Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer
2012
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial
2011
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
2010
Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas
2005
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others
2016
HeterogeneousHER2Gene Amplification
2011
Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study
2014
Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells.
1996
Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.
2009
Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy.
2010
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
2008
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
2013
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.
2018
Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial
2011
Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers
2004